Diabetes

ADA 2022: The protective effect of finerenone on cardiovascular and renal outcomes was not affected by initial HbA1c levels or T2D duration in analysis of data from the FIDELITY pooled cohort.

ADA 2022: Younger age, insulin use, higher HbA1c, and higher diabetes distress were found to be associated with CGM uptake in prospective study.

ADA 2022: In a new literature review, 43% of studies included identified diabetes as a potent risk for developing post-acute sequelae of COVID-19.

The Abbott FreeStyle Libre 3 is the smallest, thinnest, and most accurate 14-day CGM with a 7.9% MARD, the company says.

Tirzepatide, a novel once-weekly GLP-1/GIP mimetic that binds to receptors and stimulates glucose-dependent insulin release, has shown superiority over many common antihyperglycemics.

SAMPLE: What was the first FDA-approved CGM system to include a fully implantable sensor to detect glucose?

Dr Diana Isaacs reviews the significance of Eversense’s recent approval for a 180-day indication and the potential role of Dexcom G7 in the diabetes treatment landscape.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, comments on the accuracy and selection of CGMs in treating diabetes and shares insight on the evolution of CGM systems over the past year.

Wade Brosius, DO, Shelton Hager, MD, and Steven Peskin, MD, answer questions relating to diabetic retinopathy screening devices and highlight novel technologies utilized in this space.

A panel of experts in the management of diabetes answer questions relating to the importance of early screening and detection of diabetic retinopathy and provide practice pearls for how to facilitate in-office screenings.

Allen Dobson, Jr., MD, FAAFP, reviews the case of a 49-year-old woman with type 2 diabetes and the panel comments on their approaches to continued care and disease prevention.

Wade Brosius, DO, and Steven Peskin, MD, review the cost of care and reimbursement schemes available to practitioners completing diabetic retinopathy screenings.

Key opinion leaders in diabetes management provide insight on recognizing and addressing barriers to care and screening for diabetic retinopathy.

Allen Dobson, Jr., MD, FAAFP, reviews the case of a 67-year-old man with type 2 diabetes and the panel discusses initial diagnosis and management.

Key opinion leaders in diabetes management comment on the practical considerations of screening in clinical practices and note the importance of creating a replicable workflow for busy practices.

An expert in the management of diabetes provides insight into common challenges leading to low rates of diabetic retinopathy screening in primary care settings, highlighting the need to increase access to care.

Wade Brosius, DO, and Steven Peskin, MD, discuss the clinical and economic burden of diabetic retinopathy, highlighting the impact on patients’ quality of life and the health care system.

Allen Dobson, Jr., MD, FAAFP; Wade Brosius, DO; and Shelton Hager, MD, provide an overview of diabetic retinopathy and discuss risk factors leading to its pathogenesis.

An expert in diabetes management discusses the role of CGMs in treating diabetes during the COVID-19 pandemic and the benefits of using CGM in telemedicine.

Dr Diana Isaacs provides insight on patient factors to consider for CGM use in diabetes treatment.

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES, reviews the advantages of CGMs in treating type 1 and type 2 diabetes and how CGMs can improve glycemic control and quality of life in patients.

DiabetesWise Pro, created at Stanford University, provides an unbranded, unbiased guide to matching diabetes technology to patient needs, access, and lifestyle.

The phase 3 EMPA-KIDNEY clinical trial had just met prespecified criteria for positive efficacy when the study's Independent Data Monitoring Committee recommended the early halt.

Glycemic variability and low time in range were associated with retinopathy, nephropathy, neuropathy, and CVD in a cohort of more than 20 000 persons, most with T2D.

US patients at high CV risk do not receive adequate evidence-based pharmacotherapy, according to large multisite cohort analysis.

Researchers in Taiwan found NOACs were associated with lower hazards of diabetes complications. and death than warfarin in persons with AF and DM.

The 2022 DSMES National Standards update focuses on reducing administrative burden on educators and improving person-centered care for patients.

The 180-day sensor life doubles the period of continuous use and cuts in half the number of CGM removals and reinsertions, without loss of accuracy.

Higher daily step counts by women aged ≥65 years was associated with reduced risk for incident diabetes, an effect that was modified by the level of stepping intensity.

These 42 factors that affect blood glucose are listed in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.